CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY BENEFITS

3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.2.3. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PORTERS FIVE FORCE ANALYSIS
3.5. CORD BLOOD TRANSPLANT FOR TREATMENT OF MEDICAL CONDITIONS

3.5.1. Current scenario

3.5.1.1. Lymphomas
3.5.1.2. Leukemias
3.5.1.3. Transplants for inherited metabolic conditions
3.5.1.4. Transplants for inherited immunological disorders
3.5.1.5. Blood cell proliferation disorders

3.5.2. Future use (Clinical trials)

3.5.2.1. Neurologic Diseases
3.5.2.2. Auto-Immune Diseases
3.5.2.3. Orthopedic Diseases
3.5.2.4. Cardiovascular Diseases
3.5.2.5. Becker Muscular Dystrophy
3.5.2.6. Stem cells & gene therapy for inherited disorders
3.5.2.7. Stem Cells & Gene Therapy for Inherited Disorders
3.5.2.8. Stem Cell Transplantation for New Indications

3.6. REGULATORY SCENARIOS

3.6.1. FDA Biologics License Application (FDA BLA)
3.6.2. American Association of Blood Banks (AABB)
3.6.3. Clinical Laboratory Improvement Amendments (CLIA)
3.6.4. American Association of Tissue Banks (AATB)
3.6.5. Joint Accreditation Committee - ISCT - EBMT (JACIE)
3.6.6. Human Tissue Authority (HTA) - UK
3.6.7. Foundation for the Accreditation of Cellular Therapy (FACT)
3.6.8. International Organization for Standardization (ISO)
3.6.9. NetCord

3.7. MARKET DYNAMICS

3.7.1. Drivers

3.7.1.1. Increase in R&D activities for application of cord blood
3.7.1.2. Rise in funds for public storage
3.7.1.3. Increase in prevalence of fatal chronic diseases

3.7.2. Restraints

3.7.2.1. Legal and ethical issues during collection
3.7.2.2. Difficulty of finding a match in the donor list
3.7.2.3. High processing and storage cost for cord blood
3.7.2.4. Lack of awareness

3.7.3. Opportunities

3.7.3.1. Advancement in therapeutic application
3.7.3.2. Untapped opportunities in developing regions
3.7.3.3. Initiatives to spread awareness

CHAPTER 4 CORD BLOOD BANKING SERVICES MARKET, BY STORAGE SERVICES

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PUBLIC CORD BLOOD BANKS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. PRIVATE CORD BLOOD BANKS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 CORD BLOOD BANKING SERVICES MARKET, BY GEOGRAPHY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. France market size and forecast
5.3.3.2. Germany market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Rest of Europe market size and forecast

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. India market size and forecast
5.4.3.4. Singapore market size and forecast
5.4.3.5. Malaysia market size and forecast
5.4.3.6. Thailand market size and forecast
5.4.3.7. Indonesia market size and forecast
5.4.3.8. Philippines market size and forecast
5.4.3.9. Hong Kong (including Macau) market size and forecast
5.4.3.10. South Korea market size and forecast
5.4.3.11. Rest of Asia-Pacific market size and forecast

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Latin America market size and forecast
5.5.3.2. Middle East and Africa market size and forecast
5.5.3.3. Rest of LAMEA market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. AMAG PHARMACEUTICALS, INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments

6.2. AMERICORD REGISTRY LLC

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments

6.3. CHINA CORD BLOOD CORPORATION

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Key strategic moves and developments

6.4. CORD BLOOD AMERICA, INC.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Key strategic moves and developments

6.5. CORDLIFE GROUP LIMITED

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance
6.5.6. Key strategic moves and developments

6.6. CORDVIDA

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments

6.7. CRYO-CELL INTERNATIONAL, INC.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance

6.8. CRYOHOLDCO DE LATINOAMERICA, S.A.P.I. DE C.V.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments

6.9. ESPERITE N.V.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance

6.10. LIFEFORCE CRYOBANK SCIENCES, INC

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Product portfolio

6.11. NATIONAL CORD BLOOD PROGRAM

6.11.1. Company overview
6.11.2. Company snapshot
6.11.3. Operating business segments

6.12. PERKINELMER, INC.

6.12.1. Company overview
6.12.2. Company snapshot
6.12.3. Operating business segments
6.12.4. Product portfolio
6.12.5. Business performance

6.13. VIRGIN GROUP LIMITED

6.13.1. Company overview
6.13.2. Company snapshot
6.13.3. Operating business segments
6.13.4. Product portfolio

6.14. VITA 34 AG

6.14.1. Company overview
6.14.2. Company snapshot
6.14.3. Operating business segments
6.14.4. Product portfolio
6.14.5. Business performance